# Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Source: https://onco.cc/trials/nct05445843/  
OnCo record `nct05445843` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of JDQ443 in non-small-cell lung cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. is a phase 2 interventional study registered as NCT05445843 by Novartis Pharmaceuticals, with 95 participants enrolled, started 2022-12-06 and due to reach its primary completion in 2024-11-04. Interventions recorded: JDQ443. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05445843
- Phase: 2
- Setting: KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 95

## Sources

- ClinicalTrials.gov NCT05445843: https://clinicaltrials.gov/study/NCT05445843

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [JDQ443](https://onco.cc/drugs/jdq443/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct05445843.json